Kierra R Butler1, Faye R Harrell2, Bridgett Rahim-Williams3, Jeffrey M Robinson4, Xuemin Zhang5, Adwoa Gyamfi6, Judith A Erlen7, Wendy A Henderson8,9. 1. Indiana University School of Medicine, Indianapolis, IN, USA. 2. The Catholic University of America, Washington, DC, USA. 3. Research Administration, Office of Research and Sponsored Programs, University of North Florida, Jacksonville, FL, USA. 4. University of Maryland Baltimore County, Baltimore, MD, USA. 5. Office of the Director, National Institutes of Health, Bethesda, MD, USA. 6. School of Nursing, University of Connecticut, Storrs, CT, USA. 7. School of Nursing, University of Pittsburgh, Pittsburgh, PA, USA. 8. School of Nursing, University of Connecticut, Storrs, CT, USA. wendy.henderson@uconn.edu. 9. School of Medicine, University of Connecticut, Farmington, CT, USA. wendy.henderson@uconn.edu.
Abstract
BACKGROUND: Persons with HIV (PWHIV) on highly active antiretroviral treatments (HAART) may require specialized care based on health and demographic indicators. This study investigated the association of comorbidities, race, weight status, and gastrointestinal (GI) and cardiovascular (CV) symptoms among PWHIV. METHODS: The Symptom Checklist, Co-Morbidity Questionnaire, and Sociodemographic Questionnaire were used to assess weight status and GI and CV symptoms among 283 PWHIV. Data were analyzed using latent class analysis on John's Macintosh Project 13 Platform. RESULTS: Participants were majority Black (50%), 69% male, and 35% AIDS diagnosed. Ages were 25 to 66. Clusters included least symptomatic status, weight gain, and weight loss by Black and non-Black participants. The non-Black weight gain cluster reported a higher incidence of AIDS (70.6% vs 38.2%), nausea (70.6% vs 17.6%), diarrhea (70.6% vs 26.5%), and shortness of breath (58.8% vs 20.6%) compared to the Black weight gain cluster. The Black weight loss cluster reported a higher incidence of CV symptoms such as chest palpitations (42.2% vs 2.7%), chest pain (44.4% vs 8.1%), and shortness of breath (73.3% vs 35.1%). Moreover, the Black weight loss cluster reported a higher incidence of all GI symptoms with the most prominent being diarrhea (71.1% vs 48.6%) compared to the non-Black weight loss cluster. CONCLUSIONS: The existing racial disparities in health-related quality of life for PWHIV may be improved through precision health and nutrition modifications. Continued research is needed investigating differential health outcomes among PWHIV on HAART. CLINICAL TRIAL REGISTRATION NUMBER: NCT00222716. Registered 22 September 2005. Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT00222716?term=NCT00222716&draw=2&rank=1.
BACKGROUND: Persons with HIV (PWHIV) on highly active antiretroviral treatments (HAART) may require specialized care based on health and demographic indicators. This study investigated the association of comorbidities, race, weight status, and gastrointestinal (GI) and cardiovascular (CV) symptoms among PWHIV. METHODS: The Symptom Checklist, Co-Morbidity Questionnaire, and Sociodemographic Questionnaire were used to assess weight status and GI and CV symptoms among 283 PWHIV. Data were analyzed using latent class analysis on John's Macintosh Project 13 Platform. RESULTS: Participants were majority Black (50%), 69% male, and 35% AIDS diagnosed. Ages were 25 to 66. Clusters included least symptomatic status, weight gain, and weight loss by Black and non-Black participants. The non-Black weight gain cluster reported a higher incidence of AIDS (70.6% vs 38.2%), nausea (70.6% vs 17.6%), diarrhea (70.6% vs 26.5%), and shortness of breath (58.8% vs 20.6%) compared to the Black weight gain cluster. The Black weight loss cluster reported a higher incidence of CV symptoms such as chest palpitations (42.2% vs 2.7%), chest pain (44.4% vs 8.1%), and shortness of breath (73.3% vs 35.1%). Moreover, the Black weight loss cluster reported a higher incidence of all GI symptoms with the most prominent being diarrhea (71.1% vs 48.6%) compared to the non-Black weight loss cluster. CONCLUSIONS: The existing racial disparities in health-related quality of life for PWHIV may be improved through precision health and nutrition modifications. Continued research is needed investigating differential health outcomes among PWHIV on HAART. CLINICAL TRIAL REGISTRATION NUMBER: NCT00222716. Registered 22 September 2005. Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT00222716?term=NCT00222716&draw=2&rank=1.
Authors: Diana A Chirinos; Luz M Garcini; Annina Seiler; Kyle W Murdock; Kristen Peek; Raymond P Stowe; Christopher Fagundes Journal: Ann Behav Med Date: 2019-08-16
Authors: Bianca Yuh; Janet Tate; Adeel A Butt; Kristina Crothers; Matthew Freiberg; David Leaf; Mary Logeais; David Rimland; Maria C Rodriguez-Barradas; Christopher Ruser; Amy C Justice Journal: Clin Infect Dis Date: 2015-03-11 Impact factor: 9.079
Authors: I W Manner; M Baekken; D Kvale; O Oektedalen; M Pedersen; S D Nielsen; P Nowak; I Os; M Trøseid Journal: HIV Med Date: 2013-01-17 Impact factor: 3.180
Authors: Winston E Abara; Lerissa Smith; Shun Zhang; Amanda J Fairchild; Harry J Heiman; George Rust Journal: Am J Public Health Date: 2014-09-11 Impact factor: 9.308